Payment overview · 2025
General Payments
$147.90
9 reported records · 7 companies
Healthcare provider profile · identity verified
Robert D Connors, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · HACKENSACK, NJ · NPI 1801030473
Verified facts
What the public records show
CMS Open Payments records show Robert D Connors, M.D. received $147.90 in general payments during 2025 across 9 reported records.
Supernus Pharmaceuticals, Inc. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Motpoly Xr, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
Aucta Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Motpoly XR as an associated drug or biological on 4378 records involving 1499 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Motpoly Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.54 | 25.4% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $33.32 | 22.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.28 | 11.0% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$15.65 | 10.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.46 | 10.4% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.21 | 10.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.44 | 9.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $147.90 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $33.32 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Motpoly XR motpoly xr |
2025 | Motpoly Xr | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
32 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Aucta Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | Motpoly XR open payments reported associated product |
CMS Open Payments — General Payments 4378 supporting records · 1499 recipient NPIs · example record 1253325729 |
Motpoly Xr · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Radicava Ors | Edaravone | 138 | 18 |
| Gabapentin | Gabapentin | 112 | 26 |
| Levetiracetam | Levetiracetam | 87 | 20 |
| Riluzole | Riluzole | 74 | 21 |
| Lacosamide | Lacosamide | 73 | 11 |
| Divalproex Sodium | Divalproex Sodium | 64 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 12 |
| Lamotrigine | Lamotrigine | 61 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 15 |
| Prednisone | Prednisone | 49 | 12 |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Clonazepam | Clonazepam | 38 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 35 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 32 | suppressed |
| Botox | Onabotulinumtoxina | 32 | 16 |
| Nurtec Odt | Rimegepant Sulfate | 29 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Clobazam | Clobazam | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 26 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 18 | suppressed |
| Evrysdi | Risdiplam | 16 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Adderall | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Adderall Xr | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Dalfampridine Er | Dalfampridine | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Keppra | Levetiracetam | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Relyvrio | Sod Phenylbutyrat/Taurursodiol | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Motpoly Xr | Lacosamide | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $147.90 · 9 records | Supernus Pharmaceuticals, Inc. | KISUNLA, Motpoly XR, QULIPTA, Qelbree, UBRELVY, VYEPTI, VYVGART HYTRULO | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Motpoly Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error